DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus

References

• Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 2009; 22:76 - 98; http://dx.doi.org/10.1128/CMR.00034-08; PMID: 19136435
   PubMed Web of Science ®Google Scholar
• Whitley RJ. Congenital cytomegalovirus infection: epidemiology and treatment. Adv Exp Med Biol 2004; 549:155 - 60; http://dx.doi.org/10.1007/978-1-4419-8993-2_21; PMID: 15250528
   PubMed Web of Science ®Google Scholar
• Stratton K, Kurch J, Lawrence R. Vaccine for the 21st Century: a tool for decision making. Washington, D.C.: National Academy Press, 2000.
   Google Scholar
• Plotkin SA, Starr SE, Friedman HM, Brayman K, Harris S, Jackson S, et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann Intern Med 1991; 114:525 - 31; http://dx.doi.org/10.7326/0003-4819-114-7-525; PMID: 1848053
   PubMed Web of Science ®Google Scholar
• Heineman TC, Schleiss M, Bernstein DI, Spaete RR, Yan L, Duke G, et al. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis 2006; 193:1350 - 60; http://dx.doi.org/10.1086/503365; PMID: 16619181
   PubMed Web of Science ®Google Scholar
• Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang M-L, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009; 360:1191 - 9; http://dx.doi.org/10.1056/NEJMoa0804749; PMID: 19297572
   PubMed Web of Science ®Google Scholar
• Abel K, Martinez J, Yue Y, Lacey SF, Wang Z, Strelow L, et al. Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques. J Virol 2011; 85:2878 - 90; http://dx.doi.org/10.1128/JVI.00883-10; PMID: 21191005
   PubMed Web of Science ®Google Scholar
• Wussow F, Yue Y, Martinez J, Deere JD, Longmate J, Herrmann A, et al. A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques. J Virol 2013; 87:1322 - 32; http://dx.doi.org/10.1128/JVI.01669-12; PMID: 23152525
   PubMed Web of Science ®Google Scholar
• Gibson L, Piccinini G, Lilleri D, Revello MG, Wang Z, Markel S, et al. Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8+ T cell responses in children with congenital or postnatal human cytomegalovirus infection. J Immunol 2004; 172:2256 - 64; PMID: 14764694
   PubMed Web of Science ®Google Scholar
• Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202:673 - 85; http://dx.doi.org/10.1084/jem.20050882; PMID: 16147978
   PubMed Web of Science ®Google Scholar
• Berencsi K, Gyulai Z, Gönczöl E, Pincus S, Cox WI, Michelson S, et al. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis 2001; 183:1171 - 9; http://dx.doi.org/10.1086/319680; PMID: 11262198
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Reap EA, Katen K, Watson A, Smith K, Norberg P, et al. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 2009; 28:484 - 93; http://dx.doi.org/10.1016/j.vaccine.2009.09.135; PMID: 19857446
   PubMed Web of Science ®Google Scholar
• Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8:247 - 58; http://dx.doi.org/10.1038/nri2274; PMID: 18323851
   PubMed Web of Science ®Google Scholar
• Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 1997; 15:617 - 48; http://dx.doi.org/10.1146/annurev.immunol.15.1.617; PMID: 9143702
   PubMed Web of Science ®Google Scholar
• Ramshaw IA, Ramsay AJ. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 2000; 21:163 - 5; http://dx.doi.org/10.1016/S0167-5699(00)01612-1; PMID: 10740236
   PubMedGoogle Scholar
• Schneider J, Gilbert SC, Hannan CM, Dégano P, Prieur E, Sheu EG, et al. Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunol Rev 1999; 170:29 - 38; http://dx.doi.org/10.1111/j.1600-065X.1999.tb01326.x; PMID: 10566139
   PubMed Web of Science ®Google Scholar
• Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol 2009; 21:346 - 51; http://dx.doi.org/10.1016/j.coi.2009.05.016; PMID: 19500964
   PubMed Web of Science ®Google Scholar
• Estcourt MJ, Ramsay AJ, Brooks A, Thomson SA, Medveckzy CJ, Ramshaw IA. Prime-boost immunization generates a high frequency, high-avidity CD8(+) cytotoxic T lymphocyte population. Int Immunol 2002; 14:31 - 7; http://dx.doi.org/10.1093/intimm/14.1.31; PMID: 11751749
   PubMed Web of Science ®Google Scholar
• McShane H. Prime-boost immunization strategies for infectious diseases. Curr Opin Mol Ther 2002; 4:23 - 7; PMID: 11883691
   PubMed Web of Science ®Google Scholar
• Hu SL, Abrams K, Barber GN, Moran P, Zarling JM, Langlois AJ, et al. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 1992; 255:456 - 9; http://dx.doi.org/10.1126/science.1531159; PMID: 1531159
   PubMed Web of Science ®Google Scholar
• Harari A, Bart PA, Stöhr W, Tapia G, Garcia M, Medjitna-Rais E, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 2008; 205:63 - 77; http://dx.doi.org/10.1084/jem.20071331; PMID: 18195071
   PubMed Web of Science ®Google Scholar
• Dunachie SJ, Walther M, Epstein JE, Keating S, Berthoud T, Andrews L, et al. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect Immun 2006; 74:5933 - 42; http://dx.doi.org/10.1128/IAI.00590-06; PMID: 16988273
   PubMed Web of Science ®Google Scholar
• Magalhaes I, Sizemore DR, Ahmed RK, Mueller S, Wehlin L, Scanga C, et al. rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector. PLoS One 2008; 3:e3790; http://dx.doi.org/10.1371/journal.pone.0003790; PMID: 19023426
   PubMed Web of Science ®Google Scholar
• Biswas S, Reddy GS, Srinivasan VA, Rangarajan PN. Preexposure efficacy of a novel combination DNA and inactivated rabies virus vaccine. Hum Gene Ther 2001; 12:1917 - 22; http://dx.doi.org/10.1089/104303401753153965; PMID: 11589833
   PubMed Web of Science ®Google Scholar
• Xiao-wen H, Shu-han S, Zhen-lin H, Jun L, Lei J, Feng-juan Z, et al. Augmented humoral and cellular immune responses of a hepatitis B DNA vaccine encoding HBsAg by protein boosting. Vaccine 2005; 23:1649 - 56; http://dx.doi.org/10.1016/j.vaccine.2004.10.013; PMID: 15705468
   PubMed Web of Science ®Google Scholar
• Spaete RR, Saxena A, Scott PI, Song GJ, Probert WS, Britt WJ, et al. Sequence requirements for proteolytic processing of glycoprotein B of human cytomegalovirus strain Towne. J Virol 1990; 64:2922 - 31; PMID: 2159553
   PubMed Web of Science ®Google Scholar
• Wang S, Chou TH, Sakhatskyy PV, Huang S, Lawrence JM, Cao H, et al. Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J Virol 2005; 79:1906 - 10; http://dx.doi.org/10.1128/JVI.79.3.1906-1910.2005; PMID: 15650214
   PubMed Web of Science ®Google Scholar
• Lu S, Wyatt R, Richmond JF, Mustafa F, Wang S, Weng J, et al. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res Hum Retroviruses 1998; 14:151 - 5; http://dx.doi.org/10.1089/aid.1998.14.151; PMID: 9462925
   PubMed Web of Science ®Google Scholar
• Shen S, Wang S, Britt WJ, Lu S. DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates. Vaccine 2007; 25:3319 - 27; http://dx.doi.org/10.1016/j.vaccine.2007.01.011; PMID: 17287056
   PubMed Web of Science ®Google Scholar
• Gyulai Z, Endresz V, Burian K, Pincus S, Toldy J, Cox WI, et al. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs. J Infect Dis 2000; 181:1537 - 46; http://dx.doi.org/10.1086/315445; PMID: 10823751
   PubMed Web of Science ®Google Scholar
• Bunde T, Kirchner A, Hoffmeister B, Habedank D, Hetzer R, Cherepnev G, et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005; 201:1031 - 6; http://dx.doi.org/10.1084/jem.20042384; PMID: 15795239
   PubMed Web of Science ®Google Scholar
• Britt WJ, Vugler LG, Butfiloski EJ, Stephens EB. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 1990; 64:1079 - 85; PMID: 2154594
   PubMed Web of Science ®Google Scholar
• Shimamura M, Mach M, Britt WJ. Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response. J Virol 2006; 80:4591 - 600; http://dx.doi.org/10.1128/JVI.80.9.4591-4600.2006; PMID: 16611919
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Smiley ML, Friedman HM, Starr SE, Fleisher GR, Wlodaver C, et al. Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet 1984; 1:528 - 30; http://dx.doi.org/10.1016/S0140-6736(84)90930-9; PMID: 6142252
   PubMed Web of Science ®Google Scholar
• Adler SP, Starr SE, Plotkin SA, Hempfling SH, Buis J, Manning ML, et al. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 1995; 171:26 - 32; http://dx.doi.org/10.1093/infdis/171.1.26; PMID: 7798679
   PubMed Web of Science ®Google Scholar
• Jacobson MA, Sinclair E, Bredt B, Agrillo L, Black D, Epling CL, et al. Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients. J Clin Virol 2006; 35:332 - 7; http://dx.doi.org/10.1016/j.jcv.2005.09.019; PMID: 16387547
   PubMed Web of Science ®Google Scholar
• Hahn G, Revello MG, Patrone M, Percivalle E, Campanini G, Sarasini A, et al. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 2004; 78:10023 - 33; http://dx.doi.org/10.1128/JVI.78.18.10023-10033.2004; PMID: 15331735
   PubMed Web of Science ®Google Scholar
• Lilja AE, Shenk T. Efficient replication of rhesus cytomegalovirus variants in multiple rhesus and human cell types. Proc Natl Acad Sci U S A 2008; 105:19950 - 5; http://dx.doi.org/10.1073/pnas.0811063106; PMID: 19064925
   PubMed Web of Science ®Google Scholar
• Cui X, Meza BP, Adler SP, McVoy MA. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 2008; 26:5760 - 6; http://dx.doi.org/10.1016/j.vaccine.2008.07.092; PMID: 18718497
   PubMed Web of Science ®Google Scholar
• Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Rev 2011; 239:62 - 84; http://dx.doi.org/10.1111/j.1600-065X.2010.00980.x; PMID: 21198665
   PubMed Web of Science ®Google Scholar
• Schleiss MR. VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection. Curr Opin Mol Ther 2009; 11:572 - 8; PMID: 19806506
   PubMed Web of Science ®Google Scholar
• Lu S, Wang S, Grimes-Serrano JM. Current progress of DNA vaccine studies in humans. Expert Rev Vaccines 2008; 7:175 - 91; http://dx.doi.org/10.1586/14760584.7.2.175; PMID: 18324888
   PubMed Web of Science ®Google Scholar
• Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence J, et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008; 26:3947 - 57; http://dx.doi.org/10.1016/j.vaccine.2007.12.060; PMID: 18724414
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Wei CJ, Hu Z, Gordon IJ, Enama ME, Hendel CS, et al, VRC 306 Study Team. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 2011; 11:916 - 24; http://dx.doi.org/10.1016/S1473-3099(11)70240-7; PMID: 21975270
   PubMed Web of Science ®Google Scholar
• Wang S, Parker C, Taaffe J, Solórzano A, García-Sastre A, Lu S. Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine 2008; 26:3626 - 33; http://dx.doi.org/10.1016/j.vaccine.2008.04.073; PMID: 18538900
   PubMed Web of Science ®Google Scholar
• Suguitan ALJ Jr., Cheng X, Wang W, Wang S, Jin H, Lu S. Influenza H5 hemagglutinin DNA primes the antibody response elicited by the live attenuated influenza A/Vietnam/1203/2004 vaccine in ferrets. PLoS One 2011; 6:e21942; http://dx.doi.org/10.1371/journal.pone.0021942; PMID: 21760928
   PubMed Web of Science ®Google Scholar
• Morello CS, Ye M, Spector DH. Development of a vaccine against murine cytomegalovirus (MCMV), consisting of plasmid DNA and formalin-inactivated MCMV, that provides long-term, complete protection against viral replication. J Virol 2002; 76:4822 - 35; http://dx.doi.org/10.1128/JVI.76.10.4822-4835.2002; PMID: 11967299
   PubMed Web of Science ®Google Scholar
• Morello CS, Ye M, Hung S, Kelley LA, Spector DH. Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge. J Virol 2005; 79:159 - 75; http://dx.doi.org/10.1128/JVI.79.1.159-175.2005; PMID: 15596812
   PubMed Web of Science ®Google Scholar
• Jacobson MA, Adler SP, Sinclair E, Black D, Smith A, Chu A, et al. A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain). Vaccine 2009; 27:1540 - 8; http://dx.doi.org/10.1016/j.vaccine.2009.01.006; PMID: 19168107
   PubMed Web of Science ®Google Scholar
• Kern F, Surel IP, Faulhaber N, Frömmel C, Schneider-Mergener J, Schönemann C, et al. Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J Virol 1999; 73:8179 - 84; PMID: 10482568
   PubMed Web of Science ®Google Scholar
• Wang Z, La Rosa C, Maas R, Ly H, Brewer J, Mekhoubad S, et al. Recombinant MVA expressing a soluble form of Glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of CMV. J Virol 2004; 78:3965 - 76; http://dx.doi.org/10.1128/JVI.78.8.3965-3976.2004; PMID: 15047812
   PubMed Web of Science ®Google Scholar
• Wang Z, La Rosa C, Mekhoubad S, Lacey SF, Villacres MC, Markel S, et al. Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells. Blood 2004; 104:847 - 56; http://dx.doi.org/10.1182/blood-2003-10-3469; PMID: 15090456
   PubMed Web of Science ®Google Scholar
• La Rosa C, Wang Z, Lacey SF, Markel SF, Sharma MC, Martinez J, et al. Characterization of host immunity to cytomegalovirus pp150 (UL32). Hum Immunol 2005; 66:116 - 26; http://dx.doi.org/10.1016/j.humimm.2004.10.008; PMID: 15694996
   PubMed Web of Science ®Google Scholar
• Wang Z, La Rosa C, Li Z, Ly H, Krishnan A, Martinez J, et al. Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1. Vaccine 2007; 25:1132 - 41; http://dx.doi.org/10.1016/j.vaccine.2006.09.067; PMID: 17049414
   PubMed Web of Science ®Google Scholar
• Lu S, Manning S, Arthos J. Antigen engineering in DNA immunization. Totowa, NJ: Humana Press, 1999:355-74.
   Google Scholar
• Wang S, Pal R, Mascola JR, Chou TH, Mboudjeka I, Shen S, et al. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 2006; 350:34 - 47; http://dx.doi.org/10.1016/j.virol.2006.02.032; PMID: 16616287
   PubMed Web of Science ®Google Scholar
• Wang S, Joshi S, Lu S. Delivery of DNA to skin by particle bombardment. Methods Mol Biol 2004; 245:185 - 96; PMID: 14707379
   PubMedGoogle Scholar
• Gonczol E, Furlini G, Ianacone J, Plotkin SA. A rapid microneutralization assay for cytomegalovirus. J Virol Methods 1986; 14:37 - 41; http://dx.doi.org/10.1016/0166-0934(86)90005-4; PMID: 3021795
   PubMed Web of Science ®Google Scholar
• Andreoni M, Faircloth M, Vugler L, Britt WJ. A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. J Virol Methods 1989; 23:157 - 67; http://dx.doi.org/10.1016/0166-0934(89)90129-8; PMID: 2542350
   PubMed Web of Science ®Google Scholar